Sabina Chiaretti

Pubblicazioni

Titolo Pubblicato in Anno
Blinatumomab and Inotuzumab Ozogamicin Sequential Use for the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia: A Real-Life Campus All Study CANCERS 2023
Incidence, treatment and outcome of central nervous system relapse in adult acute lymphoblastic leukaemia patients treated front‐line with paediatric‐inspired regimens: A retrospective multicentre Campus ALL study BRITISH JOURNAL OF HAEMATOLOGY 2023
Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: A Campus ALL study BRITISH JOURNAL OF HAEMATOLOGY 2023
Daratumumab with or without chemotherapy in relapsed and refractory acute lymphoblastic leukemia. A retrospective observational campus acute lymphoblastic leukemia study HAEMATOLOGICA 2022
Blast morphology in the diagnostic work-up of Ph-like acute lymphoblastic leukemia LEUKEMIA & LYMPHOMA 2022
Repeated infusions of escalating doses of expanded and activated autologous natural killer cells in minimal residual disease-positive Ph+ acute lymphoblastic leukemia patients. A GIMEMA phase 1 trial AMERICAN JOURNAL OF HEMATOLOGY 2022
Digital Droplet PCR Is a Reliable Tool to Improve Minimal Residual Disease Stratification in Adult Philadelphia-Negative Acute Lymphoblastic Leukemia THE JOURNAL OF MOLECULAR DIAGNOSTICS 2022
Circulating cell‐free DNA for target quantification in hematologic malignancies: Validation of a protocol to overcome pre‐analytical biases HEMATOLOGICAL ONCOLOGY 2022
Humoral and T-cell mediated response after administration of mRNA vaccine BNT162b2 in frail populations VACCINE. X 2022
Management of Relapsed/Refractory All with Inotuzumab During COVID-19. A Case Report MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES 2022
ZNF384 rearrangement is the most frequent genetic lesion in adult PH-negative and Ph-like-negative B-other acute lymphoblastic leukemia. Biological and clinical findings LEUKEMIA & LYMPHOMA 2022
Digital Droplet PCR for Minimal Residual Disease Assessment in Philadelphia-Positive Acute Lymphoblastic Leukemia Using IG/TR Genes and BCR/ABL1 as Markers. Preliminary Results of a Comparative Analysis BloodBLOOD 2022
COVID-19 infection in acute lymphoblastic leukemia over 15 months of the pandemic. A Campus ALL report HAEMATOLOGICA 2022
Levocarnitine supplementation for asparaginase-induced hepatotoxicity in adult acute lymphoblastic leukemia patients: A multicenter observational study of the campus all group LEUKEMIA RESEARCH 2022
Digital Droplet PCR Is a Reliable Tool to Improve Minimal Residual Disease Stratification in Adult Philadelphia-Negative Acute Lymphoblastic Leukemia THE JOURNAL OF MOLECULAR DIAGNOSTICS 2022
Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia THE NEW ENGLAND JOURNAL OF MEDICINE 2022
Modern Management Options for Ph+ ALL CANCERS 2022
Case report: Ponatinib as a bridge to CAR-T cells and subsequent maintenance in a patient with relapsed/refractory Philadelphia-like acute lymphoblastic leukemia FRONTIERS IN ONCOLOGY 2022
A multicenter total therapy strategy for de novo adult Philadelphia chromosome positive acute lymphoblastic leukemia patients. Final results of the GIMEMA LAL1509 protocol HAEMATOLOGICA 2021
MYB rearrangements and over-expression in T-cell acute lymphoblastic leukemia GENES, CHROMOSOMES & CANCER 2021

© Università degli Studi di Roma "La Sapienza" - Piazzale Aldo Moro 5, 00185 Roma